Literature DB >> 11900061

Multiple myeloma following an episode of community-acquired pneumococcal bacteraemia or meningitis.

H Gregersen1, G Pedersen, N Svendsen, A M Thulstrup, H T Sørensen, H C Schønheyder.   

Abstract

The risk of multiple myeloma subsequent to an episode of serious pneumococcal infection has not been ascertained. We identified 328 episodes of community-acquired pneumococcal bacteraemia and 77 episodes of pneumococcal meningitis in 227,000 persons over 40 years of age in the County of North Jutland, Denmark, in the period 1981 to 1996. The incidence rate of a subsequent diagnosis of multiple myeloma was determined by linkage to the Danish Cancer Registry. During 1,218 patient-years of follow-up in the bacteraemia cohort, 7 cases of multiple myeloma were diagnosed compared with 0.13 cases expected (standardized incidence ratio (SIR) 53.5, 95% confidence interval 21.4-111.4). During 444 patient-years of follow-up in the meningitis cohort, 4 cases of multiple myeloma were diagnosed compared with 0.05 cases expected (SIR 83.2, 95% confidence interval 22.6-214.8). Patients who survive an episode of community-acquired pneumococcal bacteraemia or meningitis are at increased risk of being diagnosed with multiple myeloma, but the absolute risk is low.

Entities:  

Mesh:

Year:  2001        PMID: 11900061

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  9 in total

Review 1.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

Review 2.  Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

3.  Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study.

Authors:  Ebba K Lindqvist; Lynn R Goldin; Ola Landgren; Cecilie Blimark; Ulf-Henrik Mellqvist; Ingemar Turesson; Anders Wahlin; Magnus Björkholm; Sigurdur Y Kristinsson
Journal:  Blood       Date:  2011-10-13       Impact factor: 22.113

Review 4.  Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance.

Authors:  Aðalbjörg Ýr Sigurbergsdóttir; Thorvardur Jon Love; Sigurður Yngvi Kristinsson
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

5.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders.

Authors:  Linda Morris Brown; Gloria Gridley; David Check; Ola Landgren
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

6.  Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study.

Authors:  Charlene M McShane; Liam J Murray; Eric A Engels; Ola Landgren; Lesley A Anderson
Journal:  Int J Cancer       Date:  2013-10-12       Impact factor: 7.396

7.  The antibiotic chloramphenicol may be an effective new agent for inhibiting the growth of multiple myeloma.

Authors:  Faqing Tian; Chunyan Wang; Meiqin Tang; Juheng Li; Xiaohui Cheng; Sihan Zhang; Delan Ji; Yingcai Huang; Huiqing Li
Journal:  Oncotarget       Date:  2016-08-09

8.  More than Meets the Eye: Bacteremic Pneumococcal Pneumonia as the Initial Presentation of Multiple Myeloma.

Authors:  Jonas Jautz; Eliska Potlukova; Franziska Zeeh; Michael Osthoff
Journal:  Am J Case Rep       Date:  2021-01-06

9.  Increased risk of incident primary cancer after Staphylococcus aureus bacteremia: A matched cohort study.

Authors:  Nanja Gotland; M L Uhre; H Sandholdt; N Mejer; L F Lundbo; A Petersen; A R Larsen; T Benfield
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.